Semaglutide's Weight Loss Effects in Obesity

NCT06825793 · Not yet recruiting

Last updated 2026-05-28

This clinical trial tested the effects of semaglutide on weight loss in adults with obesity.

Status Not yet recruiting Approved but enrollment has not started.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Non-randomized, open-label (no blinding) treatment study

Participants 56 people Planned (estimated).

Who can join Ages 18–60 · all sexes

Timeline Started 2025-02 · est. completion 2027-12

What this study is testing ClinicalTrials.gov NCT06825793 ↗

Description as written by the study sponsor.

This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.

Treatments tested

Semaglutide Subcutaneous Injection Drug

All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.

Main thing measured	Body weight
Sponsor	Beijing Chao Yang Hospital
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06825793 ↗